Division of Endocrinology, University of Buenos Aires, Buenos Aires, Argentina.
Division of Endocrinology, University of Buenos Aires, Buenos Aires, Argentina,
Arch Endocrinol Metab. 2021 Nov 3;65(3):315-321. doi: 10.20945/2359-3997000000374.
The treatment of patients with differentiated thyroid cancer (DTC) was modified in the last decade towards a more individualized approach according to the risk of recurrence (RR). We compared the outcomes of patients with low and intermediate RR (LRR and IRR) who received or did not receive radioiodine remnant ablation (RRA) after assessing the dynamic risk.
We included 307 DTC patients with LRR and IRR submitted to total thyroidectomy. All patients were reclassified according to the dynamic risk stratification (low or high). Patients with high dynamic risk received RRA (141 patients).
LRR patients who received RRA presented a frequency of structural incomplete response (SIR) of 5% at the end of the follow-up, compared to 2% in those who did not receive it (p=0.353). IRR patients treated with RRA had a frequency of SIR of 22%, compared to 5% in patients without RRA (p=0.008).
This study demonstrates the usefulness of dynamic risk assessment to decide RRA in a cohort with a long-term follow-up. The lower prevalence of SIR at the end of the follow-up in patients who did not receive RRA highlights the adequate selection of those who would not benefit from RRA, even with an intermediate risk of recurrence.
在过去十年中,根据复发风险(RR),分化型甲状腺癌(DTC)患者的治疗方法朝着更个体化的方向进行了修改。我们比较了接受或未接受放射性碘残留消融(RRA)治疗的低危和中危复发风险(LRR 和 IRR)患者的治疗效果,同时评估了动态风险。
我们纳入了 307 例 LRR 和 IRR 的 DTC 患者,他们均接受了全甲状腺切除术。所有患者均根据动态风险分层(低或高)进行重新分类。高动态风险患者接受 RRA(141 例)。
RR 患者接受 RRA 治疗后,在随访结束时结构性不完全缓解(SIR)的发生率为 5%,而未接受 RRA 治疗的患者为 2%(p=0.353)。接受 RRA 治疗的 IRR 患者 SIR 发生率为 22%,而未接受 RRA 治疗的患者为 5%(p=0.008)。
这项研究证明了动态风险评估在长期随访的患者中决定 RRA 的有用性。未接受 RRA 治疗的患者在随访结束时 SIR 的发生率较低,这突出了对那些不会从 RRA 中获益的患者的选择是合理的,即使复发风险为中危。